Sahin Ugur, BioNTech SE’s chief executive officer, sold 49,000 shares at prices from $96.09 to $96.49 per share on Sep. 15 and Sep. 16, 2026. He retained 553,209 shares afterward, while the reported sales represented about 8.1% of his prior holding.
Key Highlights
- Sahin Ugur’s post-transaction BioNTech SE holding was 553,209 shares.
- The reported sales represented about 8.1% of his prior shares holding.
- BioNTech SE CEO Ugur Sahin sold 49,000 shares.
- The sales occurred on Sep. 15 and Sep. 16, 2026.
BioNTech SE (NASDAQ: BNTX) Chief Executive Officer Sahin Ugur sold 49,000 shares at prices ranging from $96.09 to $96.49 per share. The transactions involved BioNTech SE stock held by the company’s chief executive officer. Ugur’s transactions took place on Sep. 15 and Sep. 16, 2026. The sales were split across two separate transactions. The reported price range covered $96.09 to $96.49 per share. The combined transaction Volume was 49,000 BioNTech SE shares.
Post-Sale Holding Stood at 553,209 Shares
Ugur owned 553,209 BioNTech SE shares after completing the transactions. The sold shares represented about 8.1% of his prior shares holding in BioNTech SE. BioNTech SE’s chief executive officer therefore had a remaining post-transaction position of 553,209 shares.
FAQs
Q: How many BioNTech shares did Sahin Ugur sell?
A: BioNTech SE Chief Executive Officer Sahin Ugur sold 49,000 shares. The transactions were completed at prices ranging from $96.09 to $96.49 per share.
Q: What was the impact of Sahin Ugur’s BNTX stock sale on his holdings?
A: Ugur owned 553,209 BioNTech SE shares after the transactions. The sold shares represented about 8.1% of his prior shares holding.
Q: When did Sahin Ugur sell the BioNTech shares?
A: Sahin Ugur sold the BioNTech SE shares in two separate transactions conducted on Sep. 15 and Sep. 16, 2026. The sales involved a combined 49,000 shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.